Founded in November 2010, P&K Skin Research Center was established to provide scientific and systematic technical support and information according to various customers’ demands about clinical tests for developing new ingredients as well as functional cosmetics and quasi-drugs. P&K Skin Research Center started through a strategic alliance with Daebong LS Ltd, which is the only company manufacturing and selling pharmaceutical and cosmetic and healthy functional food ingredients, and Chung-ang University Research Center for Medical Scieces, which was the first research center to own a general hospital in Korea.
P&K Skin Research Center is equipped with facilities that meet not only the KFDA and EU guidelines but also US standards. Through analyzing all functional stroma and protocol from physical through to chemical inspection techniques for pharmaceutical ingredients, and through 30 years’ history of Daebong LS, we clinically test efficacy of general cosmetic and functional ingredients and cosmetics in accordance with KFDA, EU and US guidelines. Through these scientific evaluations, we are trying to provide scientific technical support and information for consumer satisfaction about products directly applied to the skin.
We do our utmost to ensure scientific validity, objectivity and also transparency for efficacy and functionality evaluation with Daebong LS, which has abundant clinical experiences at manufacturing and analysis, especially for pharmaceutical and cosmetic ingredients, and our experts include a dermatologist of a university hospital who has various clinical test experiences.
Contact details:
City B/D 2F, 118-2 Heukseok-dong, Dongjak-gu, Seoul 156-860 Korea
The South Korean government has designated the promotion of artificial intelligence (AI)-based drug development and healthcare innovation as a national priority. This new policy aims to capitalise on Korea’s advanced…
Uloff Münster, general manager of Merck Biopharma Korea provides his insights into the Korean healthcare system. Dr Münster also discusses the drug pricing situation in Korea and the potential for…
Young Jack Lee, CEO of LSK Global PS, Korea’s largest local contract research organization (CRO) gives his insights on the evolution of the clinical research environment over the past four…
Yong-Ik Kim, president of Korea’s National Health Insurance Service (NHIS), provides an insight into the implementation of the upcoming MoonCare reforms, the government’s strategy to ensure the expansion of coverage…
Kyungjin Peter Kim, CEO of ST Pharm, provides an insight into his expansion of the company’s operations from simply a CMO into a CDMO and new drug development. He also…
Sean Kim, senior director at the Korea Research-Based Pharma Industry Association (KRPIA) gives his assessment of the role of MNCs within the pharma industry in South Korea. At the…
Roger Zbinden, head of the Swiss Business Hub Korea, explains their efforts to raise the profile of the South Korean market for Swiss business. Dr Zbinden also provides his insights…
National OncoVenture (NOV) is Korea’s Ministry of Health and Welfare funded oncology drug development program to nurture oncology innovation in the country. To maintain high access and limit costs of…
Seung-Kyou Lee, vice-president of Korea Bio gives his assessment on the current landscape for biotech firms in Korea. He also discusses Korea Bio’s programme to create a further 1000 biotech…
Young-Whan Park, president of National OncoVenture, discusses their programme to support oncology drug development in South Korea, with a view to discovering and producing a globally competitive, Korean-made oncology medicine.…
Christoph Heider, president of the European Chamber of Commerce in Korea (ECCK), discusses the organization, the need for the modernization of the Europe-South Korea Free Trade Agreement, and the future…
Southeast Asia’s notoriously strict anti-cannabis laws could be set to relax dramatically as South Korea becomes the first country in the region to legalise cannabis for medicinal use. This…